PORTRAZZA®

(Necitumumab)

Documentation

Patented
Approved 2015
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: Antagonist
Target: EGFR
Indication Category: Cancer

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA